We are pleased to announce the U.S. FDA has accepted our two New Drug Applications (NDAs) with a Priority Review designation for an investigational treatment of classic congenital adrenal hyperplasia (CAH) in children, adolescents and adults. Read more: https://lnkd.in/g2pVurx3
This is amazing news! As a mother of 2 w/ classic CAH we are looking forward to a different treatment!!
Amazing!! Congratulations to the whole team at Neurocrine Biosciences! I know how much hard work has gone into this and this is a huge win for the patients & families of those living with CAH!
This is amazing news! Congratulations
This is great news for patients and the team!! Congrats!
Congratulations, wish you all the best
🎉 Congratulations, Neurocrine Biosciences team! This is fantastic news on the acceptance of your NDAs for the treatment of congenital adrenal hyperplasia. Looking forward to the positive impact this will have on patients. 🌟 #FDA #NewDrugApplication #HealthcareInnovation
Fantastic, and congrats sir! wish you well! kd
This is great news. Congrats!
Fantastic news all.
Pharmacy Industry Expert and Practitioner
1wThis is exceptional news for patients and families living with CAH everyday.. my hope would be it also helps to bridge care across the patient lifespan!